VIENNAâ€”With actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer genomic analysis was being hailed at the St Gallen Breast Cancer Conference as a way to expand the range of individualized cancer drugs by revealing more pathways responsible for breast cancer response and outcome. Farbice AndrÃ© MD, PhD, from the Institut Gustave Roussy in Villejuif, France, discussed the scope for bridging the gap between new genomic technologies and their application in the real world with Oncology Times reporter Sarah Maxwell.
You may also like...
Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia 6 Aug, 2013 “Total Therapy” Possible Cure For Multiple Myeloma? 26 Feb, 2008 Chronic Myeloid Leukemia ‘To Become A Very Indolent Disease’: Pregnancy Possible, Transplants Avoidedâ€”Mission Accomplished? 21 Apr, 2009 World Malaria Day 2012: Dr Chi Eziefula, LSHTM: Old Drug New Hopes 24 Apr, 2012
- Previous story Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
- Next story International Research and Consensus Needed to Interpret Breast Cancer Genomics Data
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014